On this page you will find the study results from the DAWN™ study. You can quick-navigate the page by using the "table-of-contents" menu on the right side of the page
1. Study Background
The DAWN™ Programme was created because more than half of people with diabetes do not achieve good health and quality of life, despite the availability of effective medical treatments.
Filling knowledge gaps
Although a considerable amount of psychosocial research had been carried out which pointed to psychosocial issues as the reason for poor outcomes, there were no large, truly global studies to map the problem.
Important gaps in knowledge existed, particularly concerning data which would (a) allow for international comparisons of management approaches to diabetes, (b) examine the complex relationships between the stakeholders – people with diabetes and their families, the physicians, the nurses and their support teams, and (c) enable policy makers and other stakeholders to recommend changes where needed.
The DAWN™ (Diabetes Attitudes Wishes and Needs) study in 2001 was a massive collaborative undertaking involving Novo Nordisk, the International Diabetes Federation and an international expert advisory board – the largest diabetes study of its kind ever conducted.
2. Study objectives
The objectives of the DAWN™ Study were:
3. Facts & figures
The DAWN™ study 2001 is to date the largest global psychosocial diabetes study of its kind, addressing the perceptions and attitudes of more than 5,000 people with diabetes and 3,000 healthcare diabetes professionals in a total of thirteen countries.
To ensure the highest possible scientific quality of the DAWN™ Study, an international scientific advisory panel was convened under the chairmanship of Professor Sir George Alberti, then president of the International Diabetes Federation (IDF).
The study involved:
The research consisted of face-to-face or telephone interviews depending on the country, the culture and telephone penetration rate. Interviews were on average 30-50 minutes in length.
The study was conducted at a single point of time in mid-2001, and is qualitative rather than epidemiological, helping healthcare professionals and policy makers to set priorities for further research.
4. Summary key findings
The DAWN™ study provided a wealth of information which is being used for teaching and training purposes around the world. It confirmed the importance of the following factors for improving health and life quality for people with diabetes (Practical Diabetes International 2004):
5. Enhance communications
The DAWN™ study showed that healthcare providers:
6. Promote active self-management
The DAWN™ study showed that:
7. Team-based care
The DAWN™ study showed that:
8. Barriers to treatment
The DAWN™ study showed that:
9. Enable better psychological care for patients with diabetes
The DAWN™ study and related data showed that:
10. From study to action
The DAWN™ study provided a blueprint of what it means to live with diabetes and what challenges healthcare providers are facing in their efforts to help their patients control and manage their condition effectively. With these conclusive insights about critical needs and gaps, the DAWN™ study has proven itself an important platform for dialogue and partnerships and as a decision making tool to improve outcomes of diabetes care.
Novo Nordisk has so far organized four large international DAWN™ Summits, in 2002, 2003, 2006 and 2008, to set the stage for concerted advocacy and action.
Through the DAWN™ programme, Novo Nordisk promotes new partnerships to truly translate DAWN™ into action.